SecurityTYO:8316 / Sumitomo Mitsui Financial Group,inc.
Institutional Owners0

Institutional Stock Ownership and Shareholders()

Sumitomo Mitsui Financial Group,inc. (TYO:8316) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Sumitomo Mitsui Financial Group,inc. (TYO:8316) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Green light for casinos offers jackpot to Japanese companies

5h japantimes.co.jp
Now that Japan has passed a law outlining a road map for casino resorts, foreign operators from Las Vegas Sands Corp. to MGM Resorts International can start to seek out partners in their bid to tap a gaming market that may be worth as much as $25 billion. It could also be a boon for Japanese industries — from companies that oversee resort projects to construction giants building infrastructure. (13-0)

Japan Inc to chase casino stakes as key law passes -industry insiders

2018-07-20 reuters
TOKYO (Reuters) - Japanese firms are likely to pursue stakes in the country’s first casino resorts, after parliament on Friday enacted a law smoothing the way for large-scale gambling - a business expected to generate billions of dollars in revenue. (2-0)

Japan’s banks turn to new ATM strategies

2018-07-15 thestar.com.my
A WHITE truck was parked outside a supermarket in Mishima, Shizuoka Prefecture, in late June, with a notable message on its side: "Equipped with a counter and ATM". (2-1)

Nikkei rises to 1-1/2-week high on Wall Street rally

2018-07-10 thehindubusinessline
Yahoo Japan Corp was up 10 per cent after rising as much as 11.66 per cent. (2-0)

Japan stocks erase early losses as banks, shippers bought back

2018-06-26 reuters
TOKYO, June 26 (Reuters) - Japanese shares recovered after slumping to 3-1/2-week lows on Tuesday, as recently battered stocks rose on short-covering, despite worries about global trade tensions. (58-0)